Comparative Pharmacology
Head-to-head clinical analysis: JENLOGA versus MICROGESTIN 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENLOGA versus MICROGESTIN 1 20.
JENLOGA vs MICROGESTIN 1/20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
Combination oral contraceptive containing estrogen (ethinyl estradiol) and progestin (norethindrone acetate). Inhibits gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation. Also causes cervical mucus thickening and endometrial thinning.
350 mg orally once daily with food.
One tablet (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
None Documented
None Documented
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Norethindrone: 5.2-12.8 hours (mean ~8 hours); Ethinyl estradiol: 7-20 hours (mean ~13 hours); hepatic impairment prolongs.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Renal: 40% as metabolites, 20% as glucuronide and sulfate conjugates; Fecal: 35%; Biliary: <5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive